THERAPY DOSSIER · th-bf385448ed1f

Multipotent adult progenitor cells (MAPC), alone or with tissue inhibitor of matrix metalloproteinase-3 (TIMP3)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 7

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04533464 ↗Injury indicationPHASE2unknown

MultiStem for Trauma Induced Multiple Organ Failure / SIRS

Trauma

Enrolment: 156 · Results not recorded

NCT02961504 ↗PHASE2/PHASE3completed

Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem) in Patients With Ischemic Stroke (TREASURE)

Stroke, Acute

Enrolment: 206 · Results not recorded

NCT04367077 ↗PHASE2/PHASE3terminated

Phase 2/3 MultiStem Therapy in ARDS Due to COVID-19 (MACoVIA)

ARDS

Enrolment: 206 · Results not recorded

NCT01240915 ↗PHASE2completed

Phase 2 MultiStem (PF-05285401) in Moderate to Severe Ulcerative Colitis

Colitis, Ulcerative

Enrolment: 105 · Results not recorded

NCT00677222 ↗PHASE1completed

Phase I Allogeneic AMI MultiStem in Acute Myocardial Infarction

Acute Myocardial Infarction

Enrolment: 25 · Results not recorded

NCT00677859 ↗PHASE1completed

Phase I Allogeneic MultiStem in Acute Leukemia, CML or Myelodysplasia

Hematologic Malignancies

Enrolment: 36 · Results not recorded

NCT01841632 ↗PHASE1terminated

MAPC for Immunomodulation After Liver Transplantation (MiSOT-I)

Liver Transplantation

Enrolment: 3 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30251917 ↗2018Reported benefit

Multipotent Adult Progenitor Cells, but Not Tissue Inhibitor of Matrix Metalloproteinase-3, Increase Tissue Sparing and Reduce Urological Complications following Spinal Cord Injury.

RatSpinal cord injuryContusionSprague-DawleyFemaleIntravenous1 day after acute spinal cord injury

Model: Contusion spinal cord injury

Intravenous MAPC delivered 1 day after injury significantly improved tissue sparing and affected functional recovery, and reduced the incidence of urinary tract infection and antibiotic use. TIMP3 gave no significant benefit and abrogated the therapeutic effect of MAPC when co-administered

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.62. Machine-extracted fields require source verification.

Loading the evidence…